查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908709

美國口服固體製劑CDMO市場規模、佔有率和趨勢分析報告：產品、機制、治療效果、最終用途和細分市場預測（2025-2033年）

U.S. Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Product (Tablets, Capsules, Powders), By Mechanism (Immediate, Delayed), By Drug Potency, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 162 Pages | 商品交期: 2-10個工作天內

價格

美國口服固體製劑CDMO市場概述

2024年美國口服固體製劑CDMO市場規模估計為116.2億美元，預計2033年將達到239.9億美元。

預計從 2025 年到 2033 年，該市場將以 8.63% 的年複合成長率（CAGR）成長。市場成長的驅動力是人們越來越關注複雜配方，以及越來越重視成本效益和上市速度。

此外，監管合規性和品質保證標準的加強，以及小規模和虛擬製藥公司的擴張，正在推動市場成長。難溶性原料藥和先進標靶給藥系統的日益普及，顯著提升了對口服固體製劑（OSD）配方專業知識的需求。能夠管理複雜配方（例如緩釋片、複方組合藥物和奈米技術藥物遞送系統）的美國合約研發生產機構（CDMO）正在贏得全球製藥公司的外包合約。例如，2025年8月，Piramal Pharma Solutions在賓州開設了一家專門的OSD生產工廠，投資數百萬美元，旨在透過先進的製粒、壓片、片劑生產和包衣技術，支援複方組合藥物的生產並提高營運效率。透過提供先進的服務，CDMO可以幫助客戶克服配方難題，提高療效並確保產品穩定性。這使它們脫穎而出，最佳化了工廠產能，並與尋求高價值解決方案的創新者建立了長期夥伴關係。

此外，製藥公司面臨著加快產品上市速度、降低營運成本和確保高品質標準的壓力。將口服固體製劑(OSD) 的生產外包給美國本土的合約研發生產機構 (CDMO) 可以讓企業利用其專業知識、最佳化資源並簡化供應鏈，從而實現更快、更有效率的產品開發。例如，2024 年 9 月，賽默飛世爾科技投資 2,200 萬美元，用於擴建其位於俄亥俄州辛辛那提和奧勒岡州本德的 OSD 研發和生產基地。此次擴建增強了其 CDMO 和合約研究機構 (CRO) 網路內的早期研發、製劑設計和測試能力。此外，與 CDMO 合作還能幫助企業避免維修成本。因此，能夠提供從製劑開發、規模化生產到商業化生產和包裝等全方位服務的 CDMO，在加速產品上市方面具有策略優勢。

此外，美國食品藥物管理局 (FDA) 的嚴格監管和不斷發展的全球品質標準是推動製藥企業將口服固體製劑(OSD) 生產外包給美國合約研發生產機構 (CDMO) 的關鍵因素。維持內部監管專業知識和基礎設施成本高昂且複雜，因此製藥公司傾向於依賴擁有良好合規記錄的合作夥伴。此外，符合現行藥品生產品質管理規範 (cGMP)、隨時準備接受 FDA 檢查並滿足國際品質要求的 CDMO 能夠降低風險、審核準備就緒並確保產品安全性。這種卓越的監管能力能夠建立客戶信任，並將 CDMO 定位為首選的外包合作夥伴。因此，企業可以期待持續的合約、長期的合作關係以及市場信譽的提升。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國口服固體製劑CDMO市場變數、趨勢與範圍

  • 市場譜系展望
    • 母市場展望
    • 相關市場展望
  • 市場動態
  • 科技趨勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL 分析與 SWOT 分析

第4章：美國口服固體製劑CDMO市場：產品估算與趨勢分析

  • 美國口服固體製劑CDMO市場：產品差異分析
  • 美國口服固體製劑CDMO市場規模及產品趨勢分析（2021-2033年）
  • 藥片
    • 壓縮片劑
    • 口溶錠（ODT）
    • 咀嚼片
    • 雙層或三層片劑
    • 舌下或口腔片
    • 其他
  • 膠囊
    • 硬明膠膠囊
    • 軟膠囊
  • 粉末
  • 顆粒
  • 其他

第5章：美國口服固體製劑CDMO市場：機制評估與趨勢分析

  • 美國口服固體製劑CDMO市場：依機制區分的差異分析
  • 美國口服固體製劑CDMO市場規模及趨勢分析（依作用機制分類，2021-2033年）
  • 即時發布
  • 緩釋性
  • 控釋

第6章：美國口服固體製劑CDMO市場：依技術分類的估算與趨勢分析

  • 美國口服固體製劑CDMO市場：技術變革分析
  • 美國口服固體製劑CDMO市場規模及趨勢分析（依技術分類，2021-2033年）
  • 造粒技術
  • 壓縮技術
  • 封裝技術
  • 塗層技術
  • 連續製造技術
  • 其他

第7章：美國口服固體製劑CDMO市場：藥物療效評估與趨勢分析

  • 美國口服固體製劑CDMO市場：藥物療效差異分析
  • 美國口服固體製劑CDMO市場規模及趨勢分析（依治療適應症分類，2021-2033年）
  • 高效藥物
  • 中等效力藥物
  • 低效藥物

第8章：美國口服固體製劑CDMO市場：依最終用途分類的估算與趨勢分析

  • 美國口服固體製劑CDMO市場：依最終用途分類的差異分析
  • 美國口服固體製劑CDMO市場規模及應用趨勢分析（2021-2033年）
  • 主要企業
  • 小規模
  • 其他

第9章 競爭情勢

  • 主要參與者的分類
    • Market Leaders
    • Emerging Players
  • 2024年市場佔有率/評估分析（熱力圖分析）
  • 公司簡介
    • Lonza
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Catalent Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Boehringer Ingelheim
    • Piramal Pharma Solutions
    • Aenova Group
    • Almac Group
    • Jubilant Pharmova Limited
    • AbbVie Contract Manufacturing
    • Quotient Sciences
    • SPI Pharma
    • DPT Laboratories Ltd.
    • Alcami Corporation
Product Code: GVR-4-68040-831-5

U.S. Oral Solid Dosage CDMO Market Summary

The U.S. oral solid dosage CDMO market size was estimated at USD 11.62 billion in 2024 and is projected to reach USD 23.99 billion in 2033, growing at a CAGR of 8.63% from 2025 to 2033. The market growth is driven by an increasing focus on complex formulations, along with a growing emphasis on cost efficiency and speed-to-market.

In addition, increasing regulatory compliance and quality assurance standards, as well as the expansion of small and virtual pharma companies, are propelling market growth. The growing prevalence of poorly soluble APIs and advanced targeted drug delivery systems has driven significant demand for specialized expertise in oral solid dosage (OSD) formulations. U.S. contract development and manufacturing organizations (CDMOs) that can manage complex formulations such as controlled-release tablets, fixed-dose combinations, and nanotechnology in drug delivery are attracting outsourcing contracts from global pharmaceutical companies. For instance, in August 2025, Piramal Pharma Solutions inaugurated a dedicated OSD suite in Pennsylvania, investing millions to support fixed-dose combination production and enhance operational efficiency through advanced granulation, compression, tableting, and coating capabilities. Thus, by offering these sophisticated services, CDMOs help clients overcome formulation challenges, improve therapeutic efficacy, and ensure product stability, differentiating themselves, optimizing facility capacity, and building long-term partnerships with innovators seeking high-value solutions.

Further, pharmaceutical companies face pressure to reduce time-to-market, operational costs, and ensure high-quality standards for their products. Outsourcing oral solid dosage (OSD) manufacturing to U.S.-based CDMOs allows companies to utilize specialized expertise, optimize resources, and streamline supply chains, enabling faster and more efficient product development. For instance, in September 2024, Thermo Fisher Scientific invested USD 22 million to expand OSD development and manufacturing at Cincinnati, Ohio, and Bend, Oregon, enhancing early-stage R&D, formulation, and testing capabilities within its CDMO and CRO network. Furthermore, by collaborating with CDMOs, companies can avoid the costs of building and maintaining in-house facilities and regulatory capabilities. Therefore, CDMOs that provide comprehensive services, from formulation development and scale-up to commercial manufacturing and packaging, offer a strategic advantage for accelerating product launches.

Moreover, stringent FDA regulations and evolving global quality standards are major drivers for outsourcing oral solid dosage (OSD) manufacturing to U.S. CDMOs. Maintaining in-house regulatory expertise and infrastructure is expensive and complex, prompting pharmaceutical companies to rely on partners with proven compliance track records. In addition, CDMOs adhering to cGMP, FDA inspection readiness, and international quality requirements provide risk mitigation, audit preparedness, and consistent product safety. This regulatory excellence builds client trust and positions CDMOs as preferred outsourcing partners. As a result, companies gain recurring contracts, long-term collaborations, and enhanced market credibility.

U.S. Oral Solid Dosage CDMO Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. oral solid dosage CDMO market report based on product, mechanism, technology, drug potency, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Tablets
    • Compressed Tablets
    • Orally Disintegrating Tablets (ODT)
    • Chewable Tablets
    • Bi-layer or Tri-layer Tablets
    • Sublingual or Buccal Tablets
    • Others
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
  • Powders
  • Granules
  • Others
  • Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Immediate Release
  • Delayed Release
  • Controlled Release
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Granulation Technologies
  • Compression Technologies
  • Encapsulation Technologies
  • Coating Technologies
  • Continuous Manufacturing Technologies
  • Others
  • Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)
  • High Potent Drugs
  • Moderate Potent Drugs
  • Low Potent Drugs
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Large Size Companies
  • Medium & Small Size Companies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism
    • 1.2.3. Technology
    • 1.2.4. Drug Potency
    • 1.2.5. End use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Oral Solid Dosage CDMO Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for One-Stop-Shop CMOs
      • 3.2.1.2. Growing Demand for Generic and Specialty Oral Solid Drugs
      • 3.2.1.3. Expansion of Outsourced Pharmaceutical Manufacturing
      • 3.2.1.4. Technological Advancements in Formulation and Process Development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Strict Approval Criteria by Regulatory Authorities
      • 3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
      • 3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Oral Solid Dosage CDMO Market Segment Dashboard
  • 4.2. U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
  • 4.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Tablets
    • 4.4.1. Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Compressed Tablets
      • 4.4.2.1. Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Orally Disintegrating Tablets (ODT)
      • 4.4.3.1. Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Chewable Tablets
      • 4.4.4.1. Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Bi-layer or Tri-layer Tablets
      • 4.4.5.1. Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Sublingual or Buccal Tablets
      • 4.4.6.1. Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Capsules
    • 4.5.1. Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Hard Gelatin Capsules
      • 4.5.2.1. Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Soft Gelatin Capsules
      • 4.5.3.1. Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Powder
    • 4.6.1. Powder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Granules
    • 4.7.1. Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis

  • 5.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 5.2. U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
  • 5.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
  • 5.4. Immediate Release
    • 5.4.1. Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Delayed Release
    • 5.5.1. Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Controlled Release
    • 5.6.1. Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Oral Solid Dosage CDMO Market: Technology Estimates & Trend Analysis

  • 6.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 6.2. U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
  • 6.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 6.4. Granulation Technologies
    • 6.4.1. Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Compression Technologies
    • 6.5.1. Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Encapsulation Technologies
    • 6.6.1. Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Coating Technologies
    • 6.7.1. Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Continuous Manufacturing Technologies
    • 6.8.1. Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis

  • 7.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 7.2. U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
  • 7.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2021 to 2033 (USD Million)
  • 7.4. High Potent Drugs
    • 7.4.1. High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Moderate Potent Drugs
    • 7.5.1. Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Low Potent Drugs
    • 7.6.1. Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 8.2. U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
  • 8.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.4. Large Size Companies
    • 8.4.1. Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Medium & Small Size Companies
    • 8.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Key Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 9.3. Company Profiles
    • 9.3.1. Lonza
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Cambrex Corporation
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Catalent Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Siegfried Holding AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Recipharm AB
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. CordenPharma International
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Boehringer Ingelheim
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Piramal Pharma Solutions
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Aenova Group
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Almac Group
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Jubilant Pharmova Limited
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. AbbVie Contract Manufacturing
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Quotient Sciences
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. SPI Pharma
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. DPT Laboratories Ltd.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. Alcami Corporation
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 4. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Mechanism, 2021 - 2033 (USD Million)
  • Table 5. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Drug Potency, 2021 - 2033 (USD Million)
  • Table 6. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Oral Solid Dosage CDMO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Oral Solid Dosage CDMO Market: Product Outlook And Key Takeaways
  • Fig. 20 U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
  • Fig. 21 Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Powders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Oral Solid Dosage CDMO Market: Mechanism Outlook And Key Takeaways
  • Fig. 35 U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
  • Fig. 36 Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Oral Solid Dosage CDMO Market: Technology Outlook And Key Takeaways
  • Fig. 40 U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
  • Fig. 41 Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Oral Solid Dosage CDMO Market: Drug Potency Outlook And Key Takeaways
  • Fig. 48 U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
  • Fig. 49 High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 U.S. Oral Solid Dosage CDMO Market: End Use Outlook And Key Takeaways
  • Fig. 53 U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
  • Fig. 54 Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)